Comparing two placements of a glaucoma drainage tube in the eye
Tests where a glaucoma drainage tube is placed in adults with glaucoma.
Plain-language title generated from the registry record
Registry title: Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Key facts
- Where
- Baltimore, Boston, Buffalo, Chapel Hill, Miami, San Francisco, and Walnut Creek, United StatesSee the 7 sites
Where in United States
- Wilmer Eye Institute, Johns Hopkins UniversityBaltimore, United StatesTaking people
- Massachusetts Eye and EarBoston, United StatesTaking people
- University of Buffalo/State University of New YorkBuffalo, United StatesTaking people
- University of North Carolina at Chapel HillChapel Hill, United StatesTaking people
- Bascom Palmer Eye InstituteMiami, United StatesTaking people
- University of California San FranciscoSan Francisco, United StatesTaking people
- Diablo Eye AssociatesWalnut Creek, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pennsylvania
- Trial code
- NCT05924477
- Record updated
- 14 July 2026
- Original description
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.Read full original descriptionShow less
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.
Inclusion: Medically uncontrolled glaucoma requiring GDD or GDD combined with phacoemulsification as the planned surgical procedure; Candidate for GDD implantation for ciliary sulcus and AC tube; Age greater than or equal to 18 years old.
Exclusion: Preexisting corneal condition that would affect the corneal endothelium or previous corneal transplant; Previous GDD, Xen Gel Stent or Preserflo MicroShunt removed less than 6 months before surgery; Previous trabeculectomy and/or minimally invasive glaucoma surgery within the past 6 months; Need for glaucoma surgery combined with other ocular procedures (i.e. corneal transplant, or retinal surgery) or anticipated need for additional ocular surgery; Presence or history of Cypass Micro-Stent; Presence of nanophthalmos, uncontrolled uveitis, silicone oil, Sturge-Weber syndrome or other conditions associated with elevated episcleral venous pressure; Presence of GDD implantation, Xen Gel Stent, of Preserflo MicroShunt; AC intraocular lens; Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits; No light perception vision in the study eye or fellow eye visual acuity < 20/200.